Protalix BioTherapeutics
PLX
PLX
45 hedge funds and large institutions have $141M invested in Protalix BioTherapeutics in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
12% less capital invested
Capital invested by funds: $159M → $141M (-$18.4M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
98% less call options, than puts
Call options by funds: $40K | Put options by funds: $2.2M
Holders
45
Holding in Top 10
1
Calls
$40K
Puts
$2.2M
Top Buyers
| 1 | +$2.34M | |
| 2 | +$1.48M | |
| 3 | +$1.43M | |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$817K |
| 5 |
First Eagle Investment Management
New York
|
+$778K |
Top Sellers
| 1 | -$1.43M | |
| 2 | -$1.23M | |
| 3 | -$913K | |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$786K |
| 5 |
D.E. Shaw & Co
New York
|
-$554K |